- Home
- RCKT vs IMAB Comparison
RCKT vs IMAB Comparison
Compare RCKT & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- IMAB
- Stock Information
- Founded
- RCKT 1999
- IMAB 2014
- Country
- RCKT United States
- IMAB United States
- Employees
- RCKT N/A
- IMAB N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- IMAB Health Care
- Exchange
- RCKT Nasdaq
- IMAB Nasdaq
- Market Cap
- RCKT 328.6M
- IMAB 384.6M
- IPO Year
- RCKT N/A
- IMAB 2020
- Fundamental
- Price
- RCKT $3.28
- IMAB $4.38
- Analyst Decision
- RCKT Buy
- IMAB Strong Buy
- Analyst Count
- RCKT 13
- IMAB 4
- Target Price
- RCKT $12.96
- IMAB $6.75
- AVG Volume (30 Days)
- RCKT 5.9M
- IMAB 2.1M
- Earning Date
- RCKT 11-06-2025
- IMAB 11-02-2025
- Dividend Yield
- RCKT N/A
- IMAB N/A
- EPS Growth
- RCKT N/A
- IMAB N/A
- EPS
- RCKT N/A
- IMAB N/A
- Revenue
- RCKT N/A
- IMAB N/A
- Revenue This Year
- RCKT N/A
- IMAB N/A
- Revenue Next Year
- RCKT $108.43
- IMAB N/A
- P/E Ratio
- RCKT N/A
- IMAB N/A
- Revenue Growth
- RCKT N/A
- IMAB N/A
- 52 Week Low
- RCKT $2.19
- IMAB $0.60
- 52 Week High
- RCKT $22.01
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- RCKT 51.09
- IMAB 54.65
- Support Level
- RCKT $3.16
- IMAB $4.17
- Resistance Level
- RCKT $3.40
- IMAB $4.69
- Average True Range (ATR)
- RCKT 0.27
- IMAB 0.53
- MACD
- RCKT -0.01
- IMAB -0.12
- Stochastic Oscillator
- RCKT 32.79
- IMAB 25.44
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).